Publication
As most people in the broiler industry know, necrotic enteritis (NE) is a devastating disease characterized by severe gut inflammation and sudden death, with mortality rates as high as 50% within a flock.
Economic losses due to NE extend far beyond mortality rates, however. Subclinical infection, characterized by extensive damage to the mucosal lining, leads to poor digestion and absorption of food, reduced weight gain and a decline in feed conversion.
The causative agent of NE is Clostridium perfringens, a gram-positive, anaerobic, spore-forming bacterium, which is part of the normal intestinal microflora of broiler chickens. The ability of the bacterium to cause disease depends on a variety of predisposing factors that create a favorable environment for C. perfringens to proliferate. Accordingly, the intestinal numbers of C. perfringens of healthy chickens compared to afflicted chickens can differ by several orders of magnitude.
The rapid death caused by NE often prevents treatment of the disease. Conventional diagnosis requires an invasive procedure that involves a combination of bird dissection, gram staining of mucosal scrapings, and double zone hemolysis.
Because NE is associated with an increase in C. perfringens loads in the intestinal tract, a non-invasive method to monitor C. perfringens levels before clinical symptoms are observed could help in effectively preventing and treating the disease.
To determine whether non-invasive monitoring in fecal samples could detect an increase in C. perfringens levels in birds with subclinical or clinical infection, Ancera scientists conducted a pen trial at Ozark Avian Research in Gravette, Arkansas.
Using a model system, they challenged chickens with a virulent strain of C. perfringens, either alone or after pre-challenge with Eimeria maxima oocysts, which cause coccidiosis, to induce NE. Control groups received either antibiotics and an ionophore anti-coccidial or an Coccidiosis vaccine.
Investigators collected fecal samples for C. perfringens enumeration on scheduled days throughout the trial. They also performed lesion scoring on 25 birds in each group (out of 100 birds per pen) at the end of the 21-day challenge period.
Although severe disease was not observed in the study, researchers observed higher lesion scores in C. perfringens-challenged birds both with and without E. maxima pre-challenge corroborated with an increase in average C. perfringens counts in fecal samples compared to the medicated or vaccinated birds (Fig. 1).
Investigators challenged 100 birds were each given either antibiotics and an ionophore (T1), Coccivac-B52 vaccine (T2), a virulent strain of C. perfringens (T3), or purified Eimeria maxima oocysts followed by a virulent strain of C. perfringens (T4). The average C. perfringens counts in fecal samples from birds in treatment groups T3 and T4 were higher than in treatment groups T1 and T2 (A), which correlated with higher average lesion scores (B) in birds.
Conventional plate-based methods for analysis can be labor-intensive and time consuming. To enable high-throughput sample monitoring, Ancera has applied proprietary, ferrofluid-driven, dynamic separation technology on the PIPER instrument – a machine that combines cell transport technology with molecular techniques for food production applications -- to concentrate, image and count labeled cells of interest in a complex sample (Fig. 2). The assay uses fluorescence in situ hybridization (FISH) to distinguish between C. perfringens and other bacteria, including other Clostridium species.
All sample-processing steps are contained within a single-use cartridge, eliminating the potential for cross-contamination and need for routine instrument clean-up. Automated microscopy to identify and count labeled cells simplifies analysis and removes potential sources of operator error.
Unlike traditional flow cytometers. which are prone to clogging, PIPER does not require sample clean-up prior to loading it on the instrument. The entire assay, including specific labeling using fluorescent-labeled probe and analysis on PIPER, takes less than 3 hours from the time of sample receipt.
This assay can be paired with Ancera’s PIPER coccidia assay to measure oocyst levels and C. perfringens levels in the same flocks at the same time, providing a more granular understanding of the interplay between these two gut pathogens in the development of NE.
Necrotic enteritis compromises the health and welfare of poultry and the economic vitality of the poultry industry. Ancera’s non-invasive PIPER assay delivers preemptive disease identification and efficient monitoring at scale.
To learn more, get in touch with an Ancera expert and start monitoring your flocks.
Live Production Performance
Forward looking visibility for your live production team
Get visibility into the impact of gut health with Coccidia System Monitoring. Investigational-quality data generated on a routine basis, for deployment at scale across your house, farm, complex, and corporation. Built to empower live production and technical experts to lower costs and improve margins by delivering actionable insights 6-10 weeks ahead of current practices.
Microbial Security
New visibility into risk and untapped productivity
Use 21st century technology to understand the real microbial risk with Salmonella System Monitoring. Capture the complete food safety profile across the entire supply chain. Give your technical decision-makers the power to implement practical, profit oriented changes.
.png)
